India's Pharmaceutical Sector
Global Position and Policy Context
India is the world's third-largest pharmaceutical producer by volume and holds approximately 20% of the global generics market by volume. The sector contributes around $27 billion in exports annually (2023-24), making it one of India's top export earners. "Pharmacy of the World" is a widely used descriptor reflecting India's role as a key supplier of generic medicines to developing countries and multilateral procurement agencies.
India's pharmaceutical competitiveness depends on regulatory efficiency — delays in approvals translate to delayed market entry, lost export windows, and higher costs. Key regulatory bottlenecks historically identified: - Long approval timelines (CDSCO average new drug approval: 12-24 months vs. US FDA target of 12 months) - Sequential rather than parallel review processes - Mandatory waiting for foreign Phase I data before domestic trials (removed by NDCT Rules, 2019) - Manual/paper-heavy submission processes (being digitised via SUGAM portal)
Government initiatives to strengthen pharma: - Pharmaceuticals & Medical Devices Policy 2017: targets India as global pharma hub - Production Linked Incentive (PLI) scheme for pharmaceuticals: Rs. 15,000 crore for bulk drugs (APIs) and finished dosage forms - Scheme for Promotion of Bulk Drug Parks: reduces API import dependence (India imports ~70% of APIs from China)
- India: third-largest pharma producer globally by volume; second-largest by number of US FDA-approved plants outside the US
- Generics market: India supplies ~50% of Africa's drug requirements and ~40% of US generic drug requirements
- SUGAM portal: CDSCO's online drug approval and licensing platform
- PLI for pharma: approved June 2021; target 41 selected pharmaceutical companies; minimum incremental sales threshold-based incentives
- API import from China: ~68-70% of India's API requirements; identified as strategic vulnerability post-COVID-19
● Tracked since February 01, 2026 · last seen June 23, 2026 · updates as the daily brief publishes